1-(3,5-Bis(trifluoromethyl)phenyl)-3-benzoylthiourea | 499197-64-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-Bis(trifluoromethyl)phenyl)-3-benzoylthiourea
• 英文别名: N-[[3,5-bis(trifluoromethyl)phenyl]carbamothioyl]benzamide
• CAS: 499197-64-7
• 化学式: C₁₆H₁₀F₆N₂OS
• 分子量: 392.325
• InChiKey: KJALYPVPNHXDOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-(3,5-Bis(trifluoromethyl)phenyl)-3-benzoylthiourea 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 生成 1-[3,5-双(三氟甲基)苯基]硫脲
  参考文献：
  名称：

  Synthesis and antitumor evaluation of 5-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(tert-butyl)-N-arylthiazol-2-amines

  摘要：

  设计靶向化合物作为抗肿瘤药物的策略。

  DOI：

  10.1039/c6md00234j
• 作为产物：
  描述：

  苯甲酰氯 以 丙酮 为溶剂， 反应 0.75h， 生成 1-(3,5-Bis(trifluoromethyl)phenyl)-3-benzoylthiourea
  参考文献：
  名称：

  设计，合成和评估2-氨基噻唑衍生物作为鞘氨醇激酶抑制剂

  摘要：

  鞘氨醇激酶（SphK1，SphK2）是鞘氨醇-1-磷酸酯（S1P）的主要调节剂，鞘氨醇-1-磷酸酯是一种参与多种生理和病理生理功能的多效脂质介体。SphK是新型抗癌和抗炎剂的靶标，这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病。本文中，我们描述了氨基噻唑类SphK抑制剂的设计，合成和评估。通过使用已知的SKI-II支架进行一系列修饰来定义结构-活性关系，已经发现了有效的抑制剂。我们确定了N-（4-甲基噻唑-2-基）-（2,4'-bithiazol）-2'-胺（24，ST-1803 ; IC 50 值：7.3μM（SphK1），6.5μM（SphK2））有望成为进一步体内研究和结构开发的有希望的候选者。

  DOI：

  10.1016/j.bmc.2014.07.044

文献信息

• Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors
  作者：Dominik Vogt、Julia Weber、Katja Ihlefeld、Astrid Brüggerhoff、Ewgenij Proschak、Holger Stark

  DOI：10.1016/j.bmc.2014.07.044

  日期：2014.10

  Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole

  鞘氨醇激酶（SphK1，SphK2）是鞘氨醇-1-磷酸酯（S1P）的主要调节剂，鞘氨醇-1-磷酸酯是一种参与多种生理和病理生理功能的多效脂质介体。SphK是新型抗癌和抗炎剂的靶标，这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病。本文中，我们描述了氨基噻唑类SphK抑制剂的设计，合成和评估。通过使用已知的SKI-II支架进行一系列修饰来定义结构-活性关系，已经发现了有效的抑制剂。我们确定了N-（4-甲基噻唑-2-基）-（2,4'-bithiazol）-2'-胺（24，ST-1803 ; IC 50 值：7.3μM（SphK1），6.5μM（SphK2））有望成为进一步体内研究和结构开发的有希望的候选者。
• Synthesis and antitumor evaluation of 5-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(tert-butyl)-N-arylthiazol-2-amines
  作者：Z. L. Wu、Y. L. Fang、Y. T. Tang、M. W. Xiao、J. Ye、G. X. Li、A. X. Hu

  DOI：10.1039/c6md00234j

  日期：——

  The strategy for designing target compounds as antitumor agents.

  设计靶向化合物作为抗肿瘤药物的策略。
• Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism
  作者：Carmen B. Rödl、Dominik Vogt、Simon B.M. Kretschmer、Katja Ihlefeld、Sebastian Barzen、Astrid Brüggerhoff、Janosch Achenbach、Ewgenij Proschak、Dieter Steinhilber、Holger Stark、Bettina Hofmann

  DOI：10.1016/j.ejmech.2014.07.025

  日期：2014.9

  Eicosanoids like leukotrienes and prostaglandins play a considerable role in inflammation. Produced within the arachidonic acid (AA) cascade, these lipid mediators are involved in the pathogenesis of pain as well as acute and chronic inflammatory diseases like rheumatoid arthritis and asthma. With regard to the lipid cross-talk within the AA pathway, a promising approach for an effective anti-inflammatory therapy is the development of inhibitors targeting more than one enzyme of this cascade. Within this study, thirty N-4-diaryl-1,3-thiazole-2-amine based compounds with different substitution patterns were synthesized and tested in various cell-based assays to investigate their activity and selectivity profile concerning five key enzymes involved in eicosanoid metabolism (5-, 12-, 15-lipoxygenase (LO), cyclooxygenase-1 and -2 (COX-1/-2)). With compound 7, 2-(4-phenyl)thiazol-2-ylamino)phenol (ST-1355), a multi-target ligand targeting all tested enzymes is presented, whereas compound 9, 2-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol (ST-1705), represents a potent and selective 5-LO and COX-2 inhibitor with an IC50 value of 0.9 ± 0.2 μM (5-LO) and a residual activity of 9.1 ± 1.1% at 10 μM (COX-2 product formation). The promising characteristics and the additional non-cytotoxic profile of both compounds reveal new lead structures for the treatment of eicosanoid-mediated diseases.